News from ico therapeutics inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 19, 2014, 07:00 ET

iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

VANCOUVER, Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported results...

Jun 30, 2014, 07:00 ET

iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders

VANCOUVER, June 30, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that all...

Jun 09, 2014, 08:00 ET

iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema

VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line...

May 29, 2014, 17:00 ET

iCo Therapeutics Announces First Quarter 2014 Financial Results

VANCOUVER, May 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...

Apr 29, 2014, 07:00 ET

iCo Therapeutics Announces Poster Presentation at ARVO

VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research...

Apr 24, 2014, 17:00 ET

iCo Therapeutics Announces Year End 2013 Financial Results

VANCOUVER, April 24, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results...

Mar 05, 2014, 07:00 ET

iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month...

Feb 25, 2014, 13:15 ET

iCo Therapeutics Announces DTC Approval

VANCOUVER, Feb. 25, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced that its...

Jan 27, 2014, 10:03 ET

iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing

VANCOUVER, Jan. 27, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) announced today that it has...

Jan 22, 2014, 08:42 ET

iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing

VANCOUVER, Jan. 22, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSX-V: ICO) (OTCQX: ICOTF) is pleased to announce today...

Jan 21, 2014, 17:00 ET

iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering

VANCOUVER, Jan. 21, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or the "Company") (TSXV: ICO) (OTCQX: ICOTF) announced today that it has...

Dec 20, 2013, 07:00 ET

iCo Therapeutics Begins Trading on the OTCQX Marketplace

VANCOUVER, Dec. 20, 2013 /PRNewswire/ - iCo Therapeutics (TSXV: ICO) (OTCQX: ICOTF), announced that its common shares will begin trading today on...

Dec 12, 2013, 11:42 ET

iCo Therapeutics Announces Program and Intellectual Property Advancements for Oral Amphotericin B

VANCOUVER, Dec. 12, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today announced that on November 26, 2013, U.S. patent 8,592,382 was...

Sep 05, 2013, 17:06 ET

iCo Therapeutics Grants Options to a Director

VANCOUVER, Sept. 5, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO), today announced that on September 5, 2013 the...

Sep 04, 2013, 07:00 ET

iCo Therapeutics to Present at the Rodman & Renshaw 2013 Annual Global Investment Conference

VANCOUVER, Sept. 4, 2013 /PRNewswire/ - iCo Therapeutics Inc. (TSX-V: ICO), today announced it will be presenting at the Rodman & Renshaw...

Aug 26, 2013, 17:00 ET

iCo Therapeutics Announces Second Quarter 2013 Financial Results

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013....

Jun 18, 2013, 07:00 ET

iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed...

Sep 26, 2011, 07:45 ET

iCo Therapeutics and JDRF Partner to Investigate iCo-007 in Diabetic Macular Edema

VANCOUVER, Sept. 26, 2011 /PRNewswire/ - iCo Therapeutics Inc. (TSXV: ICO) today announced that the company has entered into a research...

Dec 11, 2009, 09:00 ET

iCo Therapeutics Provides Phase 1 Diabetic Macular Edema (DME) Clinical Trial Update and Phase 2 Trial Guidance

VANCOUVER, Dec. 11 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) - iCo Therapeutics ("iCo") is pleased to announce that its Phase 1...

Feb 09, 2009, 16:30 ET

iCo Therapeutics Closes $1.3 Million Private Placement

VANCOUVER, Feb. 9 /PRNewswire-FirstCall/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce the completion of a $1,292,500 non-brokered...